OS Therapies OSTX 深 沪
等待开盘 10-07 09:30:00 美东时间
1.47
-0.155
-9.54%
华盛通- 最 高2.015
- 今 开1.725
- 成交量 595.68万股
- 最 低 1.4602
- 昨 收 1.625
- 总市值 0
- 52周最高 2.25
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.15
- 委 比 83.24%
- 总股本 --
- 历史最高 7.00
- 量 比 15.64
- 振 幅 34.14%
- 历史最低 1.15
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OS Therapies Appoints Frank Knuettel II As CFO
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced the appointment of Kerry Clem as Chief Commercial
10-01 20:34
Earnings Scheduled For May 18, 2026
Companies Reporting Before The Bell • Compugen (NASDAQ:CGEN) is likely to repor...
05-18 19:11
OS Therapies Advances OST‑HER2 Toward BLA; FDA Elevates Meeting To Type B Pre‑BLA
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New York, New
03-09 19:45
OS Therapies Bone Cancer Trial Data Strengthens FDA Case
OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eligibility for a valuable priority review voucher.
01-16 01:30
OS Therapies Intends To Spin Off OS Animal Health Into Standalone Public Entity
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced its intent to spin off OS Animal Health, Inc. (OSAH) into a standalone public
2025-11-20 20:46
EF Hutton Maintains Buy on OS Therapies, Maintains $21 Price Target
EF Hutton analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $21 price target.
2024-09-16 23:59
EF Hutton Initiates Coverage On OS Therapies with Buy Rating, Announces Price Target of $21
EF Hutton analyst Jason Kolbert initiates coverage on OS Therapies (AMEX:OSTX) with a Buy rating and announces Price Target of $21.
2024-09-03 21:01
OS Therapies Announced That The Last Patient Enrolled In AOST-2121 Clinical Trial Of OST-HER2 In Recurred, Resected Osteosarcoma Has Received Its Last Treatment Dose, Primary Endpoint Analysis Is Expected By Early In The Fourth Quarter Of 2024
This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Event Free Survival primary endpoint analysis by early in the fourth quarter of 2024. Concurrently, the Company will close all clinical trial sites and lock the database in preparation for dat...
2024-08-29 19:58
